Ketorolac Baxter

Ketorolac Trometamol, the active ingredient in Ketorolac Baxter, is a nonsteroidal anti-inflammatory drug presented as a sterile injectable solution for intramuscular and intravenous use. It provides short‑term relief of moderate to severe acute pain, especially after surgery, in adult patients.

GNH USA supplies Ketorolac Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability and regulatory support across multiple regions.

Ketorolac acts on the cyclooxygenase pathway to relieve pain and inflammation, and is indicated for the following clinical situations.

Post‑operative pain: provides short‑term relief of moderate to severe pain after surgical procedures. Acute musculoskeletal pain: reduces pain intensity in severe injuries or trauma. Dental surgery pain: controls pain following oral surgical interventions.

Ketorolac may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Headache - Dizziness - Injection site pain

Serious or Rare Side Effects: - Gastrointestinal bleeding - Renal impairment - Severe allergic reaction (anaphylaxis) - Cardiovascular thrombotic events

When using Ketorolac, clinicians should observe several safety considerations to minimize risk.

Renal function: assess baseline renal status and avoid prolonged use in patients with impairment. Bleeding risk: avoid in individuals with active ulcers, coagulopathy, or concurrent anticoagulant therapy. Pregnancy: contraindicated in the third trimester and should be used only if benefits outweigh risks during earlier trimesters. Concomitant NSAIDs: limit combined use to reduce gastrointestinal toxicity. Duration of therapy: restrict to a maximum of five days to lower risk of adverse events. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ketorolac can interact with several drug classes, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, heparin): increased risk of serious bleeding. - Selective COX‑2 inhibitors (e.g., celecoxib): additive renal toxicity. - Lithium: ketorolac may raise lithium serum concentrations, risking toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function, monitor creatinine. - Diuretics: potential for electrolyte disturbances and reduced renal clearance. - Methotrexate: decreased clearance leading to toxicity.